Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00079391 · OUTCOME

Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies · Source last updated 2015-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
First 60 days

What was measured

Incidence of acute Graft versus host disease (GVHD) grades II-IV (before day 60 T cell add back) Modified "Glucksberg" grading

Analysis population: Per protocol

Groups in this outcome

Bone Marrow Transplantation Using "Nexell Isolex 300i"

Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bone Marrow Transplantation Using "Nexell Isolex 300i"49

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bone Marrow Transplantation Using "Nexell Isolex 300i"20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        20
denoms
  1. counts
    1. group Id
      OG000
      value
      49
    units
    Participants
description
Incidence of acute Graft versus host disease (GVHD) grades II-IV (before day 60 T cell add back) Modified "Glucksberg" grading
groups
  1. description
    Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.
    id
    OG000
    title
    Bone Marrow Transplantation Using "Nexell Isolex 300i"
param Type
NUMBER
population Description
Per protocol
reporting Status
POSTED
time Frame
First 60 days
title
Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice